RxDoctor Payments DataLook up a doctor →

Dominika Szwedo, MD

Pulmonary Disease · North Little Rock, ARNPI 1952549602

Payments from drug & device makers

$16,679in general payments, 2019–2025

Across 826 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$3K
  • Boehringer Ingelheim$2K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$805
  • Sanofi$772
  • plus $7K from 40 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK161$2,736
AstraZeneca(2 entities)144$2,608
Boehringer Ingelheim94$1,857
Actelion Pharmaceuticals US, Inc.44$1,374
Regeneron Healthcare Solutions, Inc.34$805
Sanofi35$772
Mallinckrodt Hospital Products Inc.25$723
Grifols USA, LLC31$670
Mylan Specialty L.p.32$551
United Therapeutics Corporation24$544
Baxter Healthcare21$449
Insmed, Inc.17$360
Genentech USA, Inc.18$304
Merck11$228
Sanofi-aventis U.S. LLC3$222
Mallinckrodt Enterprises LLC12$206
Johnson & Johnson(2 entities)9$203
Verona Pharma, Inc.8$196
Advanced Respiratory, Inc11$176
AbbVie(2 entities)11$172
Philips North America LLC10$162
Shire North American Group Inc9$145
Viatris Specialty LLC6$139
Steris Corporation1$123
Pfizer8$120
Amgen5$100
Paratek Pharmaceuticals, Inc.4$83
Jazz Pharmaceuticals Inc.4$77
Takeda Pharmaceuticals U.S.A., Inc.4$75
Harmony Biosciences LLC4$68
Kyowa Kirin, Inc.4$65
Bayer2$51
Upsher-smith Laboratories LLC3$42
Liquidia Technologies, Inc.2$36
Vifor Pharma, Inc.2$34
Optinose US, Inc.2$32
Pulmonx Corporation1$29
Electromed, Inc.2$23
Melinta Therapeutics, LLC1$20
Shionogi Inc1$19
Eisai Inc.1$17
E.r. Squibb & Sons, L.L.C.1$14
Sandoz1$14
Nevro Corp.1$13
Teleflex LLC1$13
Teva Pharmaceuticals USA, Inc.1$12

How this compares

$16,679 in reported general payments places this provider in the 85th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas →

Medicare billing

Part B allowed, 2024
$221,743
Medicare patients
510
Services billed
7,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in North Little Rock

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →